Siao Sun1, Raji R Annadi2, Imran Chaudhri3, Kiran Munir3, Janos Hajagos4, Joel Saltz4, Minh Hoai2, Sandeep K Mallipattu5, Richard Moffitt4, Farrukh M Koraishy5. 1. Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York. 2. Department of Computer Science, Stony Brook University, Stony Brook, New York. 3. Department of Medicine, Stony Brook University, Stony Brook, New York. 4. Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York. 5. Division of Nephrology and Hypertension, Department of Medicine, Stony Brook University, Stony Brook, New York.
Abstract
Background: Severe AKI is strongly associated with poor outcomes in coronavirus disease 2019 (COVID-19), but data on renal recovery are lacking. Methods: We retrospectively analyzed these associations in 3299 hospitalized patients (1338 with COVID-19 and 1961 with acute respiratory illness but who tested negative for COVID-19). Uni- and multivariable analyses were used to study mortality and recovery after Kidney Disease Improving Global Outcomes Stages 2 and 3 AKI (AKI-2/3), and Machine Learning was used to predict AKI and recovery using admission data. Long-term renal function and other outcomes were studied in a subgroup of AKI-2/3 survivors. Results: Among the 172 COVID-19-negative patients with AKI-2/3, 74% had partial and 44% complete renal recovery, whereas 12% died. Among 255 COVID-19 positive patients with AKI-2/3, lower recovery and higher mortality were noted (51% partial renal recovery, 25% complete renal recovery, 24% died). On multivariable analysis, intensive care unit admission and acute respiratory distress syndrome were associated with nonrecovery, and recovery was significantly associated with survival in COVID-19-positive patients. With Machine Learning, we were able to predict recovery from COVID-19-associated AKI-2/3 with an average precision of 0.62, and the strongest predictors of recovery were initial arterial partial pressure of oxygen and carbon dioxide, serum creatinine, potassium, lymphocyte count, and creatine phosphokinase. At 12-month follow-up, among 52 survivors with AKI-2/3, 26% COVID-19-positive and 24% COVID-19-negative patients had incident or progressive CKD. Conclusions: Recovery from COVID-19-associated moderate/severe AKI can be predicted using admission data and is associated with severity of respiratory disease and in-hospital death. The risk of CKD might be similar between COVID-19-positive and -negative patients.
Background: Severe AKI is strongly associated with poor outcomes in coronavirus disease 2019 (COVID-19), but data on renal recovery are lacking. Methods: We retrospectively analyzed these associations in 3299 hospitalized patients (1338 with COVID-19 and 1961 with acute respiratory illness but who tested negative for COVID-19). Uni- and multivariable analyses were used to study mortality and recovery after Kidney Disease Improving Global Outcomes Stages 2 and 3 AKI (AKI-2/3), and Machine Learning was used to predict AKI and recovery using admission data. Long-term renal function and other outcomes were studied in a subgroup of AKI-2/3 survivors. Results: Among the 172 COVID-19-negative patients with AKI-2/3, 74% had partial and 44% complete renal recovery, whereas 12% died. Among 255 COVID-19 positive patients with AKI-2/3, lower recovery and higher mortality were noted (51% partial renal recovery, 25% complete renal recovery, 24% died). On multivariable analysis, intensive care unit admission and acute respiratory distress syndrome were associated with nonrecovery, and recovery was significantly associated with survival in COVID-19-positive patients. With Machine Learning, we were able to predict recovery from COVID-19-associated AKI-2/3 with an average precision of 0.62, and the strongest predictors of recovery were initial arterial partial pressure of oxygen and carbon dioxide, serum creatinine, potassium, lymphocyte count, and creatine phosphokinase. At 12-month follow-up, among 52 survivors with AKI-2/3, 26% COVID-19-positive and 24% COVID-19-negative patients had incident or progressive CKD. Conclusions: Recovery from COVID-19-associated moderate/severe AKI can be predicted using admission data and is associated with severity of respiratory disease and in-hospital death. The risk of CKD might be similar between COVID-19-positive and -negative patients.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Lakhmir S Chawla; Rinaldo Bellomo; Azra Bihorac; Stuart L Goldstein; Edward D Siew; Sean M Bagshaw; David Bittleman; Dinna Cruz; Zoltan Endre; Robert L Fitzgerald; Lui Forni; Sandra L Kane-Gill; Eric Hoste; Jay Koyner; Kathleen D Liu; Etienne Macedo; Ravindra Mehta; Patrick Murray; Mitra Nadim; Marlies Ostermann; Paul M Palevsky; Neesh Pannu; Mitchell Rosner; Ron Wald; Alexander Zarbock; Claudio Ronco; John A Kellum Journal: Nat Rev Nephrol Date: 2017-02-27 Impact factor: 28.314
Authors: Charles E Hobson; Sinan Yavas; Mark S Segal; Jesse D Schold; Curtis G Tribble; A Joseph Layon; Azra Bihorac Journal: Circulation Date: 2009-04-27 Impact factor: 29.690
Authors: Jia H Ng; Jamie S Hirsch; Azzour Hazzan; Rimda Wanchoo; Hitesh H Shah; Deepa A Malieckal; Daniel W Ross; Purva Sharma; Vipulbhai Sakhiya; Steven Fishbane; Kenar D Jhaveri Journal: Am J Kidney Dis Date: 2020-09-19 Impact factor: 8.860
Authors: Duvuru Geetha; Andreas Kronbichler; Megan Rutter; Divya Bajpai; Steven Menez; Annemarie Weissenbacher; Shuchi Anand; Eugene Lin; Nicholas Carlson; Stephen Sozio; Kevin Fowler; Ray Bignall; Kathryn Ducharlet; Elliot K Tannor; Eranga Wijewickrama; Muhammad I A Hafidz; Vladimir Tesar; Robert Hoover; Deidra Crews; Charles Varnell; Lara Danziger-Isakov; Vivekanand Jha; Sumit Mohan; Chirag Parikh; Valerie Luyckx Journal: Nat Rev Nephrol Date: 2022-08-24 Impact factor: 42.439